The Comeback Pharma Keeps Missing

A figure presented at ENDO 2026 in Chicago has stayed with me for weeks. In the largest claims analysis of its kind, researchers tracked more than 60,000 adults who started a GLP-1 for type 2 diabetes. By the two-year mark, most had stopped at some point. Here is the part our industry tends to skip […]